M&A outlook for pharma in 2025
For a strong 2025, dealmaking should be central to the life sciences strategy, says EY’s annual M&A report.
List view / Grid view
For a strong 2025, dealmaking should be central to the life sciences strategy, says EY’s annual M&A report.
The new acquisition by GSK could enable major advancement in the standard of care for gastrointestinal stromal tumours (GIST) after nearly two decades.